Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on August 13, 2025
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 13, 2025
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types …
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
GlobeNewswire
·
August 13, 2025
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- …
Aterian Reports 2025 Second Quarter Financial Results and Provides Guidance for the Second Half of 2025
GlobeNewswire
·
August 13, 2025
SUMMIT, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a consumer products company, today announced financial results for the second quarter ended June 30, 2025 (“Q2 2025”) and provided net revenue and …
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
GlobeNewswire
·
August 13, 2025
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to …
Odysight.ai Reports Financial Results for The First Half of 2025 and Provides Business Update
GlobeNewswire
·
August 13, 2025
OMER, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the first half of 2025 and …
Wallchain Launches Free Mindshare Leaderboard for All CT accounts
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- – Wallchain, one of the leading AttentionFI and InfoFi projects, is announcing the launch of free leaderboards for every person on crypto Twitter/X. Some crypto projects spend millions and wait months to launch …
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell …
dLocal announces appointment of Chief Financial Officer
GlobeNewswire
·
August 13, 2025
MONTEVIDEO, Uruguay, Aug. 13, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology - first payments platform, today announced the appointment of Guillermo López Pérez as Chief Financial Officer, who will join …
dLocal Reports 2025 Second Quarter Financial Results
GlobeNewswire
·
August 13, 2025
TPV at record high of US$9.2 billion, growing more than 50% YoY for the third consecutive quarter. Brazil and Mexico posted solid results, while growth remains fastest in the rest of our geographies, leading to increased diversification. Consistent …
AirJoule Technologies Announces Second Quarter 2025 Results
GlobeNewswire
·
August 13, 2025
RONAN, Mont., Aug. 13, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading technology platform that unleashes the power of water from air, today announced its second quarter 2025 …
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 …
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 13, 2025
Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the …
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the …
Codexis Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to …
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 13, 2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC …
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 13, 2025
- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival (OS) observed at 6 months in ongoing …
Roadzen Reports Best Fiscal Q1 in Company History with 22% Revenue Growth, 92% Lower Net Loss, and 50% Adjusted EBITDA Improvement Over the Same Quarter Last Year
GlobeNewswire
·
August 13, 2025
1. Record Fiscal Q1 Revenue Sets Stage for the Year Ahead First quarter fiscal 2026 revenue increased 22% to $10.9 million from $8.9 million last year – the strongest first quarter revenue on record for Roadzen, driven by growth in India and the U.S., …
HeartCore Reports Financial Results for Second Quarter and Six Months Ended June 30, 2025
GlobeNewswire
·
August 13, 2025
NEW YORK and TOKYO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the second quarter …
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
GlobeNewswire
·
August 13, 2025
CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster …
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE …